With BIO Asia–Taiwan just around the corner, biotech is buzzing—but one keyword is stealing the spotlight like never before: Exosomes.

Once a niche topic, exosomes and extracellular vesicles (EVs) have burst into mainstream conversation. The market for exosome-based diagnostics and therapeutics is projected to hit USD $3.4 billion by 2032, with an eye-popping CAGR of 30%.

But here’s the catch:
Despite the growing hype, no exosome therapy or diagnostic has yet received regulatory approval. Industry standards for manufacturing, characterization, and regulation remain inconsistent across the globe—yet bold claims are already spreading like wildfire in the aesthetics, wellness, and cosmetics sectors.

Global Bio & Investment brings you a concise summary of the latest expert forum discussions:
What's signal, what's noise—and what must the industry solve before the exosome gold rush becomes a true pipeline?

Read more in our latest issue (Volume 128):
https://news.gbimonthly.com/tw/magazine/show.php?num=138